CASSIOPE: A prospective noninterventional study of cabozantinib treatment following prior vascular endothelial growth factor (VEGF) -targeted therapy in patients with advanced renal cell carcinoma (aRCC).

被引：0
|
作者：
Staehler, Michael D.
Bigot, Pierre
Barthelemy, Philippe
Hamberg, Paul
Suarez, Cristina
Eymard, Jean-Christophe
Gajate, Pablo
Perrot, Valerie
Qvick, Bryan
Dutailly, Pascale
Procopio, Giuseppe
机构：
[1] Univ Munich, Munich, Germany
[2] Ctr Hosp Univ Angers, Angers, France
[3] Inst Cancerol Strasbourg Europe, Strasbourg, France
[4] Franciscus Gasthuis & Vlietland, Dept Med Oncol, Rotterdam, Netherlands
[5] Vall dHebron Univ Hosp, Barcelona, Spain
[6] Univ Autonoma Barcelona, Inst Oncol, Barcelona, Spain
[7] Inst Jean Godinot, Reims, France
[8] Hosp Univ Ramon y Cajal, Madrid, Spain
[9] Ipsen Pharma, Boulogne, France
[10] Ipsen, Paris, France
[11] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4529
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CASSIOPE: A real-world study assessing the use of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after vascular endothelial growth factor (VEGF)-targeted therapy in Europe
    Staehler, Michael D.
    Hamberg, Paul
    Bigot, Pierre
    Suarez, Cristina
    Barthelemy, Philippe
    Eymard, Jean-Christophe
    Laramas, Mathieu
    Pioger, Naila Taguieva
    Gross-Goupil, Marine
    Rink, Michael
    Masini, Cristina
    De Vivo, Rocco
    Gajate, Pablo
    Azzabi, Ashraf
    Procopio, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience
    Osanto, Susanne
    van der Hulle, Tom
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2018, 10 (03) : 109 - 123
  • [3] Interim analysis of CASSIOPE: A real-world study of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy in Europe
    Procopio, G.
    Hamberg, P.
    Bigot, P.
    Suarez, C.
    Barthelemy, P.
    Eymard, J-C.
    Masini, C.
    Borau, P. Gajate
    Dutailly, P.
    Perrot, V.
    Staehler, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S571 - S571
  • [4] Real-world study of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy (CASSIOPE): Interim data for patients who had received prior nivolumab
    Procopio, G.
    Hamberg, P.
    Bigot, P.
    Suarez Rodriguez, C.
    Barthelemy, P.
    Eymard, J-C.
    Masini, C.
    Gajate Borau, P.
    Dutailly, P.
    Perrot, V.
    Staehler, M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S695 - S696
  • [5] Real-world study of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy (CASSIOPE): interim data for patients who had received prior nivolumab
    Hamberg, Paul
    Bigot, Pierre
    Suarez, Cristina
    Barthelemy, Philippe
    Eymard, Jean-Christophe
    Masini, Cristina
    Gajate, Pablo
    Dutailly, Pascale
    Perrot, Valerie
    Procopio, Giuseppe
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 103 - 103
  • [6] Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma
    Escudier, Bernard
    Albiges, Laurence
    [J]. DRUGS, 2011, 71 (09) : 1179 - 1191
  • [7] Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma
    Bernard Escudier
    Laurence Albiges
    [J]. Drugs, 2011, 71 : 1179 - 1191
  • [8] Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England
    Brown, Janet
    Harrow, Brooke
    Marciniak, Anne
    McCarthy, Christine
    Houchard, Aude
    Cirneanu, Lori
    Protheroe, Andrew
    [J]. DRUGS-REAL WORLD OUTCOMES, 2024, 11 (02) : 195 - 207
  • [9] COST-EFFECTIVENESS IN ENGLAND OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (ARCC) AFTER FAILURE OF PRIOR THERAPY
    Lister, J.
    Vataire, A.
    Amzal, B.
    Dinet, J.
    Meng, J.
    Karcher, H.
    Gabriel, S.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A441 - A441
  • [10] Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma
    Zhu, Y.
    Hong, Y. P.
    Zhang, H. L.
    Shi, G. H.
    Xiao, W. J.
    Wang, Z. H.
    Yao, X. D.
    Zhang, S. L.
    Dai, B.
    Ye, D. W.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (11) : 1901 - 1907
12345